EGFR and lung carcinoma: High TMB in EGFR‐mutant lung cancers was linked to a significantly shorter overall survival in patients treated with EGFR‐TKIs.18 This finding stands in contrast to what is observed for TMB and treatment with immune checkpoint inhibitors.